Yayıncı "MDPI" Biomedical Engineering için listeleme
Toplam kayıt 6, listelenen: 1-6
-
Cytotoxicity of standardized curcuminoids mixture against epithelial ovarian cancer cell line SKOV-3
(MDPI, 2020)Herbal medicine has been in use for centuries for a wide variety of ailments; however, the efficacy of its therapeutic agents in modern medicine is currently being studied. Curcuminoids are an example of natural agents, ... -
Enhancing enzymatic properties of endoglucanase i enzyme from trichoderma reesei via swapping from cellobiohydrolase i enzyme
(MDPI, 2019)Utilizing plant-based materials as a biofuel source is an increasingly popular attempt to redesign the global energy cycle. This endeavour underlines the potential of cellulase enzymes for green energy production and ... -
Novel synthetic approaches for bisnaphthalimidopropyl (BNIP) derivatives as potential anti-parasitic agents for the treatment of leishmaniasis
(MDPI, 2019)Leishmaniasis is a neglected parasitic disease that is widely seen in more than 60 countries worldwide, including Turkey and its subcontinental region. There are several chemotherapy agents for the treatment of leishmaniasis, ... -
Radiation type- and dose-specific transcriptional responses across healthy and diseased mammalian tissues
(MDPI, 2022)Ionizing radiation (IR) is a genuine genotoxic agent and a major modality in cancer treatment. IR disrupts DNA sequences and exerts mutagenic and/or cytotoxic properties that not only alter critical cellular functions but ... -
Temperature and pH-dependent behaviors of mAb drugs: A case study for trastuzumab
(MDPI, 2022)The distortions in the high-order structure of therapeutic monoclonal antibodies (mAbs) under different environmental conditions acutely affect mAb stability, resulting in altered safety, efficacy, and shelf-life profiles. ... -
Utilization of biased G protein-coupled receptor signaling towards development of safer and personalized therapeutics
(MDPI, 2019)G protein-coupled receptors (GPCRs) are involved in a wide variety of physiological processes. Therefore, approximately 40% of currently prescribed drugs have targeted this receptor family. Discovery of beta-arrestin ...